49
Institut Carnot Curie Cancer
The Carnot certification is a recognition of excellence awarded to academic research organizations whose quality and involvement in partnership-based research have been demonstrated. Certified since 2011, Institut Carnot Curie Cancer offers industrial partners the opportunity to implement research collaborations utilizing the expertise of Institut Curie s research teams to develop innovative solutions for cancer, from therapeutic target to clinical approval.
April: first partnership with a small French company that develops innovative anticancer molecules as part of the CHICHE! program (CHallenge the Instituts Carnot
in cHemistry and hEalth! CHallengez les Instituts Carnot
en cHimie et santE !) for very small/small/medium-sized
companies that innovate in health, as part of the
FINDMED consortium.
May: collaboration with Predilife for the launch of the new generation of MammoRisk®, a test to predict the risk of breast cancer giving a polygenic score
(calculation of high risk associated with the combination of
genome variations) using a saliva sample.
May: start of an artificial intelligence (AI) project with LEO Pharma to identify risk factors for thrombosis in
patients suffering from cancer, with the aim of improving
prevention of these accidents.
20 new projects in development
30 newly announced inventions
579 active patents from 159 families
21 start-ups created, 100% of them still operating
Almost
11 M in worldwide income generated
93 new R&D collaboration contracts signed (+33% compared with 2018) for almost 7.5 million (+15% compared with 2018)
CONGRATULATIONS!
The NEOVIVA project involving Institut Curie and
Transgene, HalioDX and Traaser has been selected by the Future Investment Program (PIA subsidies granted by
the French government). Its aim is to develop an industry
for the individualized anticancer vaccine myvac™.
Two start-ups from Institut Curie were certified by PSL Tech Seed for joint funding by Bpifrance in 2019:
Honing Biosciences (secretion of cells medications for
cellular therapy) and Skiagenics (biomarkers and genome
signatures for diagnosis and prognosis of cancers).
Among the winners of the 21st edition of the national
i-Lab competition designed to support the creation of innovative technological companies are two start-ups
from Institut Curie: Honing Biosciences and SideROS.
As it seeks to identify, promote and develop all scientific, technological and medical resources in an open innovation approach, Institut Curie becomes a leading player in the transfer of oncology technologies.
Amaury Martin, Director of Industrial Development and Partnerships and Director of the Institut Carnot Curie Cancer